Understanding psychiatric disorders at a cellular and molecular level could provide a different perspective to design diagnostic and therapeutic tools searching for the origin of these disorders and the alterations they cause. Fourteen simultaneous studies from the PsychENCODE Consortium have delved into the cellular atlases of human neurodevelopment, reporting the broadest view of neuropsychiatry to date.
Bristol Myers Squibb Co. and Celgene Corp. have described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of inflammation, cancer, fibrosis, autoimmune disorders, cardiovascular disorders, metabolic disorders and cerebrovascular disorders.
Inversago Pharma Inc. has divulged cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome.
Shanghai Shenshi Wise Technology Co. Ltd. has identified potassium voltage-gated channel subfamily A member 3 (KCNA3) channel blockers reported to be useful for the treatment of inflammatory and immunological disorders.
Artivila Biopharma Co. Ltd. has synthesized macrocyclic compounds acting as cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic disease, cancer, psychiatric disorders and neurological disorders.
Kinesin-like protein KIFC1 plays a role in the clustering of centrosomes in cancer cells and is being investigated in some types of cancer, concretely in melanoma.
Amphista Therapeutics Ltd. has unveiled a new mechanism of action for the degradation of the emerging oncology target BRD9 that is differentiated from cereblon- or VHL-based PROTACs.
Abdera Therapeutics Inc. has received FDA clearance of its IND application for ABD-147, the first δ-like ligand 3 (DLL3)-targeting radiopharmaceutical for the treatment of small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma.
Podocytes are a terminally differentiated cell type located in the glomerulus. Podocyte damage and the subsequent dysregulation of podocyte proteins have been implicated in various kidney disorders. Since gene delivery to podocytes using adeno associated vectors (AAVs) has been challenging due to various technological and physiological hurdles, investigators at Purespring Therapeutics Ltd. developed an AAV gene therapy platform that allowed for effective, specific and safe delivery of transgenes to podocytes.
RSS
